The first study showed that MAVS gene expression is increased in the liver of people with NASH as compared with a non-NASH control group15; however, the second study found that the MAVS protein levels are reduced in the liver of people living with MASLD.16 In our study, we found that both mRNA and protein levels of MAVS are significantly upregulated in people with MASLD, with MAVS transcripts being positively associated with NAS and serum triglyceride levels. This evidence concerns the gene MAVS and metabolic dysfunction-associated steatohepatitis.